EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Change in the serum selenium level of patients with non-metastatic and metastatic non-small cell lung cancer (NSCLC) during radiotherapy as a predictive factor for survival

Julia Ohlinger, Dirk Vordermark, Christian Ostheimer, Matthias Bache, Therese Tzschoppe, Kamil Demircan, Lutz Schomburg, Daniel Medenwald iD, Barbara Seliger

Strahlentherapie und Onkologie · 2025-06 · 201 (6) · 616-626

DOI: 10.1007/s00066-024-02276-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift Strahlentherapie und Onkologie, online erschienen am 06.09.2024. Verfasst von Julia Ohlinger und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medical Faculty, Radiation Therapy Clinic, University Hospital Halle (Saale), Martin Luther University Halle-Wittenberg, Ernst-Grube-Straße 40, 06120…. Hauptthemen laut MEDLINE: Lung Neoplasms, Selenium, Carcinoma, Non-Small-Cell Lung, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Martin-Luther-Universität Halle-Wittenberg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung cancer remains a serious medical problem. The trace element selenium seems to be a promising prognostic marker or therapeutic option for cancer patients.

Methods

We enrolled 99 patients with histologically confirmed NSCLC undergoing radiotherapy. The serum selenium level of these patients was determined prior to irradiation (t0), after reaching 20 Gy (t1), and at the end of radiotherapy (t2). Selenium concentrations were measured with total-reflection X‑ray fluorescence (TXRF) spectroscopy. We formed three subgroups according to the change in serum selenium levels across timepoints, and Kaplan–Meier analysis was used to estimate overall survival (OS). Further subgroups were patients with/without metastatic disease. We used adjusted Cox regression models.

Results

The change in selenium concentration was especially significant between t0 and t1 for the whole study group (hazard ratio [HR] = 0.5, p = 0.03) as well as in patients with metastasized NSCLC (HR = 0.3, p = 0.04) after adjustment. The baseline selenium value in patients with non-metastasized NSCLC was associated with overall survival (HR = 0.3, p = 0.04). The change in selenium levels between t0 and t2 was significant in patients with metastatic lung cancer (HR = 0.1, p = 0.03). Patients with increased serum selenium levels during radiotherapy between the start of treatment (t0) and t1 had better OS (HR = 0.46, p = 0.05).

Conclusion

Especially patients with increasing selenium levels during radiotherapy showed an improved overall survival. Thus, serum selenium might be a predictive factor for OS in NSCLC patients. The value of supplementation of the trace element is subject to future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsSeleniumCarcinoma, Non-Small-Cell LungBiomarkers, TumorHumansFemaleMaleAgedMiddle AgedSurvival RatePrognosisSensitivity and SpecificityAged, 80 and overAdultReproducibility of ResultsRisk Factors

Stichwörter der Autor:innen

ChemotherapyImmunotherapyNutritionOverall survivalRadiation

Substanzen

SeleniumBiomarkers, Tumor

Autor:innen und Institutionen

  • Medical Faculty, Radiation Therapy Clinic, University Hospital Halle (Saale), Martin Luther University Halle-Wittenberg, Ernst-Grube-Straße 40, 06120, Halle (Saale), Germany.
  • Charité-University Medicine Berlin, Institute for Experimental Endocrinology, Berlin, Germany.
  • Medical Faculty, Radiation Therapy Clinic, University Hospital Halle (Saale), Martin Luther University Halle-Wittenberg, Ernst-Grube-Straße 40, 06120, Halle (Saale), Germany. Daniel.Medenwald@uk-halle.de.
  • Medical Faculty, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
  • Institute for Translational Immunology, Brandenburg Medical School "Theodor Fontane", Brandenburg, Germany.
  • Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.

ORCID-Profile: Daniel Medenwald

Förderung

  • Martin-Luther-Universität Halle-Wittenberg

Zitieren

APA

Ohlinger, J., Vordermark, D., Ostheimer, C., Bache, M., Tzschoppe, T., Demircan, K., Schomburg, L., Medenwald, D., & Seliger, B. (2025). Change in the serum selenium level of patients with non-metastatic and metastatic non-small cell lung cancer (NSCLC) during radiotherapy as a predictive factor for survival. Strahlentherapie und Onkologie, 201(6), 616-626. https://doi.org/10.1007/s00066-024-02276-w

Vancouver

Ohlinger J, Vordermark D, Ostheimer C, Bache M, Tzschoppe T, Demircan K, et al. Change in the serum selenium level of patients with non-metastatic and metastatic non-small cell lung cancer (NSCLC) during radiotherapy as a predictive factor for survival. Strahlentherapie und Onkologie. 2025;201(6):616-626. doi:10.1007/s00066-024-02276-w

BibTeX
@article{Ohlinger2025,
  author = {Ohlinger, Julia and Vordermark, Dirk and Ostheimer, Christian and Bache, Matthias and Tzschoppe, Therese and Demircan, Kamil and Schomburg, Lutz and Medenwald, Daniel and Seliger, Barbara},
  title = {Change in the serum selenium level of patients with non-metastatic and metastatic non-small cell lung cancer (NSCLC) during radiotherapy as a predictive factor for survival},
  journal = {Strahlentherapie und Onkologie},
  year = {2025},
  volume = {201},
  number = {6},
  pages = {616--626},
  doi = {10.1007/s00066-024-02276-w}
}
Kostenlos starten →